Nanna Witting

researcher

Nanna Witting is …
instance of (P31):
humanQ5

External links are
P496ORCID iD0000-0002-0664-0709

P69educated atAarhus Faculty of Health SciencesQ4661705
P108employerRigshospitaletQ3357360
P734family nameWittingQ21488913
WittingQ21488913
WittingQ21488913
P735given nameNannaQ16422888
NannaQ16422888
P106occupationresearcherQ1650915
P21sex or genderfemaleQ6581072

Reverse relations

author (P50)
Q53559144A PET activation study of brush-evoked allodynia in patients with nerve injury pain.
Q48695686A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy
Q35890267Aerobic Training in Patients with Congenital Myopathy
Q31032086Axial myopathy: an overlooked feature of muscle diseases.
Q60772362Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2
Q114905389Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis
Q35582438Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E
Q53634475Clinical and neurophysiological response to pharmacological treatment of DOK7 congenital myasthenia in an older patient.
Q48226149Collagen XII myopathy with rectus femoris atrophy and collagen XII retention in fibroblasts
Q52565198Congenital titinopathy: Comprehensive characterisation and pathogenic insights.
Q28542539Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease
Q41855877Deletion of exon 26 of the dystrophin gene is associated with a mild Becker muscular dystrophy phenotype.
Q60772388Differential recruitment of endogenous pain inhibitory systems in neuropathic pain patients
Q60772304Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy
Q48590768Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy.
Q60772295Endocrine function over time in patients with myotonic dystrophy type 1
Q37610554Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years
Q51162545Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy.
Q34421461Has basic research contributed to chronic pain treatment?
Q51743589High prevalence of cardiac involvement in patients with myotonic dystrophy type 1: a cross-sectional study.
Q36615476Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or 'classical' congenital myopathy.
Q30413900Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy.
Q35576188Myocardial fibrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic resonance study
Q60772312Ocular, bulbar, limb, and cardiopulmonary involvement in oculopharyngeal muscular dystrophy
Q38178549Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome.
Q54116685Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome.
Q37716090Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark
Q41588609Prevalence and phenotypes of congenital myopathy due to α-actin 1 gene mutations.
Q60772288Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study
Q60772242Reliability of the 2- and 6-minute walk tests in neuromuscular diseases
Q60772400Repetitive intradermal capsaicin: differential effect on pain and areas of allodynia and punctate hyperalgesia
Q60772354Response
Q54397896Severe axial myopathy in McArdle disease.
Q48011157The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
Q53220865Two- and 6-minute walk tests assess walking capability equally in neuromuscular diseases.

Search more.